"Plasmablastic Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells which have the immunophenotype of plasma cells and a predilection for the ORAL CAVITY.
| Descriptor ID |
D000069293
|
| MeSH Number(s) |
C04.557.386.480.150.585.500 C15.604.515.569.480.150.585.500 C20.683.515.761.480.150.585.500
|
| Concept/Terms |
Plasmablastic Lymphoma- Plasmablastic Lymphoma
- Lymphoma, Plasmablastic
- Lymphomas, Plasmablastic
- Plasmablastic Lymphomas
- Plasmablasts Diffuse Large B-cell Lymphoma
- Plasmablasts Diffuse Large B cell Lymphoma
- Plasmablastic Diffuse Large B-cell Lymphoma
- Plasmablastic Diffuse Large B cell Lymphoma
|
Below are MeSH descriptors whose meaning is more general than "Plasmablastic Lymphoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Plasmablastic Lymphoma [C04.557.386.480.150.585.500]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Plasmablastic Lymphoma [C15.604.515.569.480.150.585.500]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
- Plasmablastic Lymphoma [C20.683.515.761.480.150.585.500]
Below are MeSH descriptors whose meaning is more specific than "Plasmablastic Lymphoma".
This graph shows the total number of publications written about "Plasmablastic Lymphoma" by people in this website by year, and whether "Plasmablastic Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Plasmablastic Lymphoma" by people in Profiles.
-
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma? Hematology Am Soc Hematol Educ Program. 2025 Dec 05; 2025(1):564-570.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 02; 98(2):300-308.
-
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. Br J Haematol. 2022 07; 198(2):e32-e34.
-
Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
-
Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 10 01; 96(10):E390-E392.
-
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755.
-
Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017 11; 62:12-16.
-
Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324.